Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI362 in HFpEF or HFmrEF Combined With Obesity
NCT06862908Phase 2Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of mazdutide in heart failure with preserved ejection fraction (HFpEF), heart failure with mildly reduced ejection fraction (HFmrEF), obesity, sponsored by Innovent Biologics. Started Mar 2025; status: active, not recruiting.
02
Drugs
mazdutide
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mildly reduced ejection fraction (HFmrEF)obesity
Beyond the preview
Go deeper on NCT06862908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06862908.